Haemonetics Corp
NYSE:HAE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
47.67
87.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Haemonetics Corp
NYSE:HAE
|
3.2B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.5T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
31B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
36.2B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
121.3B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.8B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
43.8B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.5B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.5T KRW |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Haemonetics Corp
Glance View
In the realm of healthcare, Haemonetics Corp. operates as a pivotal player, bridging the gap between innovation and life-saving technology. Founded in 1971, the company has evolved to become a leader in blood management solutions, riding the wave of advanced medical technology to cater primarily to hospitals and blood collection centers. At its core, Haemonetics specializes in products and software designed to optimize the collection, processing, and surgical use of blood. Among its notable contributions are devices for blood component separation and coagulation management systems, which play a critical role in ensuring that patients around the world receive safe and effective blood therapy. Revenue streams for Haemonetics come from a diverse range of blood management systems and services. Their offerings are not limited to physical products; the company also provides comprehensive software solutions that help institutions maximize efficiencies and improve patient outcomes. With a keen focus on research and development, Haemonetics continuously innovates to meet the stringent demands of the modern healthcare landscape. Their business model thrives on a combination of direct sales, strategic partnerships, and service agreements with hospitals and blood banks, all while maintaining a strong commitment to quality and regulatory compliance. Through its strategic approach, Haemonetics not only fulfills an essential healthcare need but also crafts a sustainable financial pathway by redefining how blood and related products are managed globally.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Haemonetics Corp is 19.1%, which is above its 3-year median of 16%.
Over the last 3 years, Haemonetics Corp’s Operating Margin has increased from 13% to 19.1%. During this period, it reached a low of 12.9% on Dec 31, 2022 and a high of 19.1% on Sep 27, 2025.